枸地氯雷他定与依巴斯汀递减疗法治疗慢性荨麻疹的效果对比
|
摘要
目的对比分析枸地氯雷他定与依巴斯汀递减疗法治疗慢性荨麻疹的效果。方法选择2015年1月─2016年12月在我院进行诊治的126例慢性荨麻疹患者,随机分为2组。枸地氯雷他定组采用枸地氯雷他定递减疗法治疗,依巴斯汀组采用依巴斯汀递减疗法治疗。治疗10周后,比较2组的临床治疗效果,观察2组治疗前后的症状体征总积分、炎性介质水平以及组胺水平。停药后对2组患者随访4周,记录2组的复发率及不良反应发生率。结果枸地氯雷他定组的有效率为77.77%(49/63),与依巴斯汀组的74.60%(47/63)相比差异无统计学意义(P>0.05);枸地氯雷他定组和依巴斯汀组治疗后的症状体征总积分以及组胺水平均明显降低(P<0.05),但2组间相比差异无统计学意义(P>0.05);枸地氯雷他定组和依巴斯汀组治疗后的炎性介质水平均明显降低(P<0.05),但2组间相比差异无统计学意义(P>0.05),枸地氯雷他定组的复发率为7.94%(5/63),明显低于依巴斯汀组的19.05%(12/63,P<0.05);2组的不良反应发生率相比差异无统计学意义(P>0.05)。结论枸地氯雷他定递减疗法和依巴斯汀递减疗法治疗慢性荨麻疹的临床效果以及安全性基本相当,但与依巴斯汀相比,枸地氯雷他定降低复发率的效果明显更佳。
Objective In order to compare the effects of desloratadine citrate and ebastine in treating chronic urticaria.Methods A total of 126 cases of patients with chronic urticaria who were treated in our hospital from January 2015 to December 2016 were selected and divided into two groups randomly. Desloratadine citrate group with desloratadine citrate decreasing therapy, ebastine group were treated with ebastine decreasing therapy. After treatment for 10 weeks, the clinical effects of the two groups were compared, and the total scores of symptoms, histamine and inflammatory medium levels of the two groups were observed before and after treatment. After the drug withdrawal, the two groups were followed up for four weeks, and the recurrence rate and adverse reaction rate of the two groups were recorded. Results After treatment, the effective rate of desloratadine citrate group was 77.77%(49/63), and ebastine group 74.60%(47/63) showed no significant difference(P >0.05). Desloratadine citrate group and ebastine group after treatment of the symptoms and signs of the total score, histamine and inflammatory medium levels were significantly decreased(P<0.05), but no significant differences were found between the two groups(P>0.05). The recurrence rate of desloratadine citrate group was 7.94%(5/63), and it was significantly lower than that of ebastine group 19.05%(12/63, P<0.05). The incidence of adverse reactions of the two groups showed no significant difference(P>0.05). Conclusion The clinical effects and safety of desloratadine citrate and ebastine decreasing treatment of chronic urticariais basically the same, but compared with ebastine, desloratadine citrate can reduce the recurrence rate better.
Objective In order to compare the effects of desloratadine citrate and ebastine in treating chronic urticaria.Methods A total of 126 cases of patients with chronic urticaria who were treated in our hospital from January 2015 to December 2016 were selected and divided into two groups randomly. Desloratadine citrate group with desloratadine citrate decreasing therapy, ebastine group were treated with ebastine decreasing therapy. After treatment for 10 weeks, the clinical effects of the two groups were compared, and the total scores of symptoms, histamine and inflammatory medium levels of the two groups were observed before and after treatment. After the drug withdrawal, the two groups were followed up for four weeks, and the recurrence rate and adverse reaction rate of the two groups were recorded. Results After treatment, the effective rate of desloratadine citrate group was 77.77%(49/63), and ebastine group 74.60%(47/63) showed no significant difference(P >0.05). Desloratadine citrate group and ebastine group after treatment of the symptoms and signs of the total score, histamine and inflammatory medium levels were significantly decreased(P<0.05), but no significant differences were found between the two groups(P>0.05). The recurrence rate of desloratadine citrate group was 7.94%(5/63), and it was significantly lower than that of ebastine group 19.05%(12/63, P<0.05). The incidence of adverse reactions of the two groups showed no significant difference(P>0.05). Conclusion The clinical effects and safety of desloratadine citrate and ebastine decreasing treatment of chronic urticariais basically the same, but compared with ebastine, desloratadine citrate can reduce the recurrence rate better.
引文
[1]Powell RJ,Leech SC,Till S,et al.BSACI guideline for the management of chronic urticaria and angioedema[J].Clin Exp Allergy,2015,45:547-565.
[2]Zhang YH,Bian SN,Dermatology DO.Efficacy of Mizolastine and acupoint catgut implantation in treatment of chronic urticaria[J].Chin J Mod Med,2015,52:984-990.
[3]吕静,曹玉平,张丽君,等.组胺脱敏联合左西替利嗪治疗特发性慢性荨麻疹疗效观察[J].中国中西医结合皮肤性病学杂志,2016,15(5):304-305.
[4]中华医学会皮肤性病学分会免疫学组.中国荨麻疹诊疗指南(2014版)[J].中华皮肤科杂志,2014,47(7):388-390.
[5]Zuberbier T,Maurer M.Omalizumab for the treatment of chronic urticaria[J].Expert Rev Clin Immunol,2015,11:171.
[6]Fine LM,Bernstein JA.Guideline of Chronic Urticaria Beyond[J].Allergy Asthma Immunol Res,2016,8:396-403.
[7]刘丽明,于波,张杰.慢性自发性荨麻疹自身免疫机制研究进展[J].中华实用诊断与治疗杂志,2015,29(12):1 154-1 156.
[8]Maurer M,Church MK,Gon觭alo M,et al.Management and treatment of chronic urticaria(CU)[J].J Eur Acad Dermatol Venereol,2015,29:16-32.
[9]张飞娟,白莉.慢性荨麻疹患者外周血中白细胞介素25、17的表达及意义[J].中国中西医结合皮肤性病学杂志,2016,15(1):16-18.
[10]郭霞.慢性荨麻疹患者血液学指标的改变及对预后的影响[J].中华全科医学,2015,13(11):1 789-1 790.
[11]刘爱民,王庆兴,张步鑫,等.105例慢性荨麻疹治愈患者远期疗效随访报告[J].中国中西医结合皮肤性病学杂志,2016,15(4):215-217.
[12]黎国栋,吴洪文,赵金柳.氯雷他定联合西替利嗪治疗慢性荨麻疹的疗效及对血清Ig E水平的影响[J].医学综述,2017,23(2):406-409.
[13]何广卫,储昭兴.李家明.枸地氯雷他定抗过敏性炎症作用实验研究[J].安徽医药,2014,18(10):1 844.
[14]闫毅,刘瑞珍,徐德钢.枸地氯雷他定与依匹斯汀治疗慢性荨麻疹随机对照研究[J].中华皮肤科杂志,2015,48(1):54-56.
[15]冉春涛.左西替利嗪联合依巴斯汀治疗慢性荨麻疹对实验室指标、临床症状积分的影响及临床疗效分析[J].河北医药,2016,38(7):1 015-1 017.
[16]代金枝,周敬安,李璐,等.复方甘草酸苷联合枸地氯雷他定预防慢性荨麻疹复发的临床效果观察[J].临床合理用药杂志,2017,10(23):76-77.
[2]Zhang YH,Bian SN,Dermatology DO.Efficacy of Mizolastine and acupoint catgut implantation in treatment of chronic urticaria[J].Chin J Mod Med,2015,52:984-990.
[3]吕静,曹玉平,张丽君,等.组胺脱敏联合左西替利嗪治疗特发性慢性荨麻疹疗效观察[J].中国中西医结合皮肤性病学杂志,2016,15(5):304-305.
[4]中华医学会皮肤性病学分会免疫学组.中国荨麻疹诊疗指南(2014版)[J].中华皮肤科杂志,2014,47(7):388-390.
[5]Zuberbier T,Maurer M.Omalizumab for the treatment of chronic urticaria[J].Expert Rev Clin Immunol,2015,11:171.
[6]Fine LM,Bernstein JA.Guideline of Chronic Urticaria Beyond[J].Allergy Asthma Immunol Res,2016,8:396-403.
[7]刘丽明,于波,张杰.慢性自发性荨麻疹自身免疫机制研究进展[J].中华实用诊断与治疗杂志,2015,29(12):1 154-1 156.
[8]Maurer M,Church MK,Gon觭alo M,et al.Management and treatment of chronic urticaria(CU)[J].J Eur Acad Dermatol Venereol,2015,29:16-32.
[9]张飞娟,白莉.慢性荨麻疹患者外周血中白细胞介素25、17的表达及意义[J].中国中西医结合皮肤性病学杂志,2016,15(1):16-18.
[10]郭霞.慢性荨麻疹患者血液学指标的改变及对预后的影响[J].中华全科医学,2015,13(11):1 789-1 790.
[11]刘爱民,王庆兴,张步鑫,等.105例慢性荨麻疹治愈患者远期疗效随访报告[J].中国中西医结合皮肤性病学杂志,2016,15(4):215-217.
[12]黎国栋,吴洪文,赵金柳.氯雷他定联合西替利嗪治疗慢性荨麻疹的疗效及对血清Ig E水平的影响[J].医学综述,2017,23(2):406-409.
[13]何广卫,储昭兴.李家明.枸地氯雷他定抗过敏性炎症作用实验研究[J].安徽医药,2014,18(10):1 844.
[14]闫毅,刘瑞珍,徐德钢.枸地氯雷他定与依匹斯汀治疗慢性荨麻疹随机对照研究[J].中华皮肤科杂志,2015,48(1):54-56.
[15]冉春涛.左西替利嗪联合依巴斯汀治疗慢性荨麻疹对实验室指标、临床症状积分的影响及临床疗效分析[J].河北医药,2016,38(7):1 015-1 017.
[16]代金枝,周敬安,李璐,等.复方甘草酸苷联合枸地氯雷他定预防慢性荨麻疹复发的临床效果观察[J].临床合理用药杂志,2017,10(23):76-77.